31 results about "Staphylococcus Phages" patented technology

The invention relates to the technical field of microorganisms, and particularly relates to a Staphylococcus aureus phage and bacteriostatic application thereof. The Staphylococcus aureus phages107 is sent to China Center for Type Culture Collection for Preservation, the classification name is Staphylococcus aureus phages107, the preservation number is CCTCC NO: M2021125, the preservation date is January 21, 2021, and the address is Wuhan University, Wuhan City, China. The phages107 has high titer up to 2.31 * 10<10>PFU / mL, good pH stability, good temperature stability and wide lysis spectrum, and has lysis ability on 9 strains of Staphylococcus aureus, wherein the 9 strains of Staphylococcus aureus have certain drug resistance and no lysis ability on escherichia coli. The Staphylococcus aureus phage has specific lysis spectrum for Staphylococcus aureus, and has strong lysis ability. The Staphylococcus aureus phages107 can be used for preparation of drugs for treating Staphylococcus aureus induced dairy cow mastitis and other diseases.

The invention relates to the field of biology, in particular to novel staphylococcus aureus bacteriophages as well as a composition and application thereof, and provides four staphylococcus aureus bacteriophages including: podoviridae BP-13 with the preservation number of CCTCC NO: M 2015142; staphylococcus aureus BP-13A with the preservation number of CCTCC M2016535; podoviridae BP-14 with the preservation number of CCTCC NO: M 2015143; and podoviridae AHJD-like phage BP-39 with the preservation number of CCTCC NO: M 2015144. The four bacteriophages are strict virulent bacteriophages, can effectively kill various staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have a wide host range, but have no toxic effect on normal microbial flora, and the DNA of the bacteriophages cannot encode virulence genes. Therefore, the bacillus subtilis can be used for preventing or treating human and livestock bacterial infection caused by the staphylococcus aureus, provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect. Besides, the host range and the antibacterial efficiency of the cocktail mixture disclosed by the invention are further greatly improved.

The invention relates to staphylococcus bacteriophage and an application thereof in staphylococcal infection and particularly relates to staphylococcus bacteriophage. The staphylococcus bacteriophageis preserved in CGMCC, the preservation date of which is 27th, July, 2017, and the preservation number of CGMCC No. 14330. The bacteriophage has a relatively good splitting action on staphylococcus. The preparation can be used independently or used with cocktail to provide a safe, toxic and side effect and residual effect-free bacteriophage product source for treatment of staphylococcal infection.

The invention relates to the field of biology, in particular to novel staphylococcus aureus bacteriophages as well as a composition and application thereof, and provides four staphylococcus aureus bacteriophages, including podoviridae BP-13 with the preservation number of CCTCC NO: M 2015142. staphylococcus aureus BP-13A with the preservation number of M 2016535; podoviridae BP-14 with the preservation number of NO: M 2015143; and podoviridae AHJD-like phage BP-39 with the preservation number of NO: M 2015144. The four bacteriophages are strict virulent bacteriophages, can effectively kill various staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have a wide host range, but have no toxic effect on normal microbial flora, and the DNA of the bacteriophages cannot encode virulence genes. Therefore, the bacillus subtilis can be used for preventing or treating human and livestock bacterial infection caused by the staphylococcus aureus, provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect. In addition, the host range and the antibacterial efficiency of the cocktail mixture disclosed by the invention are further greatly improved.

The invention relates to the field of biological engineering, and in particular relates to lywallzyme (or catenase) of phage of staphylococcus aureus and an application thereof as an antibacterial material in preventing and treating bouine mastitis and controlling food pollution. The amino acid sequence of the lywallzyme of phage of staphylococcus aureus is SeqIDNO2. Zymin capable of efficiently killing staphylococcus aureus is developed by a bioengineering technique. The zymin can be used independently or with other agents to inactivate staphylococcus aureus specifically so as to provide a safe zymin source without toxic and side effects for preventing and treating bouine mastitis and controlling staphylococcus aureus pollution in food.

The invention discloses a staphylococcal phage composition and its application in medicines for staphylococcal infection diseases. Pharmaceutical compositions, feed additives, disinfectants and applications using the phage composition as the main active ingredient. The above phage composition has a strong lysing effect on bovine staphylococcus and can be used to prevent and treat diseases caused by bovine staphylococcus infection , compared with a single lytic bacteriophage, the composition greatly broadens its bactericidal range, increases its bactericidal activity, can improve the physique and disease resistance of dairy cows, and is low in cost and environmentally friendly.

The invention discloses a construction method of a recombinant adenovirus vector co-expressing SAL‑2 gene and hLYZ dual antibacterial gene, and the application of the recombinant adenovirus. The extra SAL‑2 gene and hLYZ gene were cloned into the pShuttle‑IRES‑hrGFP‑2 shuttle vector, linearized and recombined with the shuttle vector and co-transfected with the backbone vector pAdeasy‑1 into E. coli BJ5183 competent cells , making it perform homologous recombination in BJ5183, constructing the recombinant adenoviral plasmid Ad-SAL-LYZ containing the above-mentioned target gene; digesting the recombinant adenoviral plasmid with PacⅠ, and transfecting HEK293 cells through liposome-mediated transfection, High-titer recombinant adenovirus was packaged to obtain high-titer recombinant adenovirus; the joint inhibitory effect of SAL‑2 gene and hLYZ gene on the main pathogenic bacteria of dairy cow mastitis was evaluated under the mediation of adenovirus.

The invention discloses a strongly lytic Staphylococcus aureus phage RDP-SR-20001 and its application in poultry pathogenic Staphylococcus aureus infection. The present invention utilizes the double-layer plate method to obtain a Staphylococcus aureus BS‑20001 strain from diseased broiler lesion tissue of Qingdao Jimo broiler farm, and then uses Staphylococcus aureus BS‑20001 as the host to isolate gold from the farm sewage. Staphylococcus aureus phage RDP‑SR‑20001, the deposit number is CGMCCNo.21409. The Staphylococcus aureus phage RDP‑SR‑20001 provided by the present invention has a strong cracking effect on pathogenic Staphylococcus aureus BS‑20001 in the poultry breeding environment, and is used for industrial production of phages for pathogenic Staphylococcus aureus in the poultry breeding environment The control provides a phage source.

The present invention relates to the field of microorganisms, and specifically provides a new staphylococcal phage and its composition, preparation method and application. The phage is Staphylococcus aureus phage J1P1, and the preservation number is CCTCC No: M2016284; Staphylococcus aureus phage J1P2, The preservation number is CCTCC No: M2016285; the preservation number of Staphylococcus aureus phage J1P3 is CCTCC No: M2016286; the preservation number of Staphylococcus aureus phage J2-1P1 is CCTCC No: M2016287; The deposit number is CCTCC No: M2016288. The phage of the invention can prevent and treat human or animal bacterial infection diseases caused by various staphylococci, especially staphylococcus aureus, provide excellent phage resources for the development of new antibacterial preparations, and have good application and development prospects.

The invention relates to the field of biology, in particular to novel staphylococcus aureus bacteriophages as well as a composition and application thereof, and provides four staphylococcus aureus bacteriophages, comprising: podoviridae BP-13 with the preservation number of CCTCC NO: M 2015142. staphylococcus aureus BP-13A with the preservation number of M 2016535; podoviridae BP-14 with the preservation number of NO: M 2015143; and podoviridae AHJD-like phage BP-39 with the preservation number of NO: M 2015144. The four bacteriophages are strict virulent bacteriophages, can effectively kill various staphylococcus aureus such as MRSA, MSSA, BORSA and the like, have a wide host range, but have no toxic effect on normal microbial flora, and the DNA of the bacteriophages cannot encode virulence genes. Therefore, the bacillus subtilis can be used for preventing or treating human and livestock bacterial infection caused by the staphylococcus aureus, provides an excellent strain resource for developing a novel antibacterial preparation, and has a good application and development prospect. In addition, the host range and the antibacterial efficiency of the cocktail mixture disclosed by the invention are further greatly improved.

The invention provides a genetic engineering-modified staphylococcus aureus staphylophage lyase, the amino acid sequence of which is shown in SEQ ID NO:1. The invention also discloses a preparation method of the staphylococcus aureus staphylophage lyase, comprising the following concrete steps: (1) cloning the amino acid sequence shown in the SEQ ID NO:1 into a prokaryotic expression vector to obtain a recombinant plasmid; (2) transforming the recombinant plasmid obtained in the step (1) into host bacteria to obtain recombinant bacteria; (3) expressing the staphylococcus aureus staphylophage lyase by the recombinant plasmid; and (4) purifying the staphylococcus aureus staphylophage lyase obtained in the step (3). Multiple staphylococcus aureus can be specifically inactivated by independently using the genetic engineering-modified staphylococcus aureus staphylophage lyase or matching the genetic engineering-modified staphylococcus aureus staphylophage lyase with other compounds, thus providing a safe enzymic preparation source without toxic and side effects for staphylococcus aureus infection, particularly staphylococcus aureus caused dairy mastitis in the existing dairy farm control.

The invention relates to a bacteriophage and antimicrobial application thereof, in particular to a methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage and antimicrobial application thereof, and belongs to the field of bioengineering. The methicillin-resistant staphylococcus epidermidis staphylococcus aureus bacteriophage is preserved in China Center for Type Culture Collection (CCTCC), located in Wuhan University of Wuhan of China, on September 17, 2015. The collection number is staphylococcus aureus bacteriophage qdsa002 of CCTCC M2015554. The Latin scientific name is staphylococcus aureus bacteriophage qdsa002. The bacteriophage has high splitting effect on staphylococcus aureus, especially methicillin-resistant staphylococcus epidermidis staphylococcus aureus. The preparation can be used individually or compounded with other drugs, and a safe bacteriophage product source free of toxic and side effects is provided for control of methicillin-resistant staphylococcus epidermidis staphylococcus aureus contamination.